Anixa Biosciences Inc ANIX

NAS: ANIX | ISIN: US03528H1095   16:47
3,030 USD (+2,02%)
(+2,02%)   16:47

30 april 2024 · Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024 · Persbericht

18 april 2024 · Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board · Persbericht

14 maart 2024 · Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties · Persbericht

11 maart 2024 · Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress · Persbericht

12 februari 2024 · Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial · Persbericht

29 januari 2024 · Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference · Persbericht

23 januari 2024 · Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology · Persbericht

10 januari 2024 · Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024 · Persbericht

14 december 2023 · Anixa Biosciences to Present at Biotech Showcase 2024 · Persbericht

7 december 2023 · Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine · Persbericht

6 december 2023 · Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine · Persbericht

31 oktober 2023 · Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference · Persbericht

23 oktober 2023 · Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board · Persbericht

13 oktober 2023 · Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial · Persbericht

3 oktober 2023 · Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology · Persbericht

19 september 2023 · Anixa Biosciences Establishes Cancer Business Advisory Board · Persbericht

31 augustus 2023 · Anixa Biosciences to Participate in September Investor Conferences · Persbericht

28 augustus 2023 · Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial · Persbericht

14 augustus 2023 · Anixa Biosciences Announces Invited Presentation on Ovarian Cancer CAR-T Therapy at the 8th Annual CAR-TCR Summit · Persbericht

7 augustus 2023 · Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial · Persbericht

Mijn selecties